Zofran Birth Defect Lawsuit Joins Others In Massachusetts MDL

November 23, 2015 – – ZofranLegal.com reports on another update to the zofran birth defect lawsuits. In this case, a mother who initially filed her zofran lawsuit in the U.S. District Court of the Western District of Louisiana, will now be headed to join those in Boston, Massachusetts in MDL 2657. The mother, who is suing zofran manufacturer GlaxoSmithKline on behalf of her daughter, filed her case under number 6:25-cv-01815-RFD-PJH.

Details of the suit, filed on June 8th, 2015, allege that exposure to anti-nausea drug Zofran while developing in the womb caused the woman’s daughter to be born with multiple heart defects. The mother was prescribed Zofran to help combat morning sickness symptoms during her first trimester of pregnancy. This is also the time when a fetus develops much of its heart tissue.

When the infant girl was born several months later, she was diagnosed with perimembranous ventricular septal defect, atrial septal defect and intermittent tachypnea. These defects are considered serious and physicians informed the mother that her daughter would require surgery.

This case is similar to many others which allege that exposure to Zofran has caused babies to be born with severe birth defects. The defects most commonly noted in these lawsuits are: cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, clubfoot, and kidney defects.

Another ‘hot topic’ with many of the mothers and families who have filed suit centers around the fact that Zofran was never FDA-approved to treat expectant mothers, or tested for safety concerning this use. The drug was approved by the United States Food and Drug Administration to treat those suffering with nausea and vomiting after undergoing chemotherapy, radiation, and anesthesia. Since getting its approval, however, plaintiffs allege that manufacturer GSK marketed the drug to Ob/Gyns and pregnant mothers across the U.S. The medication has been prescribed to treat morning sickness in an estimated 1 million women annually.

In October of 2015, the Judicial Panel on Multidistrict Litigation approved requests that Zofran lawsuits be consolidated into an MDL under one court. This decision helps to speed up the litigation process, saving resources of those involved and avoiding duplicate discovery or different rulings from multiple judges.

As these cases await coordination for pretrial hearings, it is anticipated that others will be filed. The attorneys at Monheit Law are working to ensure that anyone who was prescribed Zofran while pregnant and who subsequently gave birth to a child with defects has the opportunity to explore their legal rights. These families and children may be entitled to compensation. Monheit Law is offering free legal consultations for anyone involved.

To obtain additional information on Zofran birth defect lawsuits, or to ask questions, please contact Attorney Michael Monheit by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005708